Krueger JG - Search Results

1

Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept.

Suárez-Fariñas M, Shah KR, Haider AS, Krueger JG, Lowes MA. Suárez-Fariñas M, et al. Among authors: krueger jg. BMC Dermatol. 2010 Feb 12;10:1. doi: 10.1186/1471-5945-10-1. BMC Dermatol. 2010. PMID: 20152045 Free PMC article. Clinical Trial.

2

Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B.

Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG. Coven TR, et al. Among authors: krueger jg. Arch Dermatol. 1997 Dec;133(12):1514-22. Arch Dermatol. 1997. PMID: 9420535 Clinical Trial.

3

Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris. Evidence that epidermal immunocytes are direct therapeutic targets.

Coven TR, Murphy FP, Gilleaudeau P, Cardinale I, Krueger JG. Coven TR, et al. Among authors: krueger jg. Arch Dermatol. 1998 Oct;134(10):1263-8. doi: 10.1001/archderm.134.10.1263. Arch Dermatol. 1998. PMID: 9801682

4

Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris.

Walters IB, Burack LH, Coven TR, Gilleaudeau P, Krueger JG. Walters IB, et al. Among authors: krueger jg. J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):893-900. doi: 10.1016/s0190-9622(99)70076-9. J Am Acad Dermatol. 1999. PMID: 10365919

5

Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes.

Murphy FP, Coven TR, Burack LH, Gilleaudeau P, Cardinale I, Auerbach R, Krueger JG. Murphy FP, et al. Among authors: krueger jg. Arch Dermatol. 1999 Dec;135(12):1495-502. doi: 10.1001/archderm.135.12.1495. Arch Dermatol. 1999. PMID: 10606055

6

The immunologic basis for the treatment of psoriasis with new biologic agents.

Krueger JG. Krueger JG. J Am Acad Dermatol. 2002 Jan;46(1):1-23; quiz 23-6. doi: 10.1067/mjd.2002.120568. J Am Acad Dermatol. 2002. PMID: 11756941 Review.

7

Treatment of inflammatory dermatoses with novel biologic agents: a primer.

Nussbaum R, Krueger JG. Nussbaum R, et al. Among authors: krueger jg. Adv Dermatol. 2002;18:45-89. Adv Dermatol. 2002. PMID: 12528402 Review. No abstract available.

8

Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: differential regulation of cytokines at the single-cell level.

Walters IB, Ozawa M, Cardinale I, Gilleaudeau P, Trepicchio WL, Bliss J, Krueger JG. Walters IB, et al. Among authors: krueger jg. Arch Dermatol. 2003 Feb;139(2):155-61. doi: 10.1001/archderm.139.2.155. Arch Dermatol. 2003. PMID: 12588221

9

A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. Carlin CS, et al. Among authors: krueger jg, krueger gg. J Am Acad Dermatol. 2004 Jun;50(6):859-66. doi: 10.1016/j.jaad.2003.09.014. J Am Acad Dermatol. 2004. PMID: 15153885

10

Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.

Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P, Lee E, Howell K, Bodary S, Dummer W, Krueger JG. Vugmeyster Y, et al. Among authors: krueger jg. Clin Immunol. 2004 Oct;113(1):38-46. doi: 10.1016/j.clim.2004.06.001. Clin Immunol. 2004. PMID: 15380528

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

455 results

Search Page